Some suppliers also offer sterile water that has been diluted with bacteriostatic ingredients to create a solution suitable for peptide reconstitution
What the FDA Has Said About BPC-157 and Compounding In September 2023, the FDA put BPC-157 in Category 2 of the 503A Interim Bulks Guidance, which stopped pharmacies from compounding it
A 2023 Cochrane review confirmed no clear benefit for stroke and noted increased adverse events requiring hospitalization in the Cerebrolysin group
The material is provided in an encapsulated solid format, intended solely as a physical containment and presentation method to facilitate controlled storage, handling, and measurement in research settings
Red flag symptoms requiring urgent assessment include progressive neuropathy, ataxia (balance problems), cognitive changes, and visual disturbances